JP Morgan Chase’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
Sell
-85,000
Closed -$8.24M 6064
2019
Q3
$8.24M Buy
+85,000
New +$8.51M ﹤0.01% 2288
2019
Q2
Sell
-12,600
Closed -$1.44M 6151
2019
Q1
$1.44M Buy
+12,600
New +$926K ﹤0.01% 3572
2018
Q4
Sell
-30,000
Closed -$1.64M 6068
2018
Q3
$1.64M Hold
30,000
﹤0.01% 3601
2018
Q2
$2.48M Sell
30,000
-22,600
-43% -$1.74M ﹤0.01% 3250
2018
Q1
$3.5M Buy
52,600
+30,000
+133% +$1.73M ﹤0.01% 2864
2017
Q4
$1.16M Buy
+22,600
New +$1.62M ﹤0.01% 3642

JP Morgan Chase's ONCE Position: Q4 2019 in Review

JP Morgan Chase sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q4 2019, closing a stake of 499,936 shares — an estimated $48.5M sold.

JP Morgan Chase first reported a position in ONCE in Q1 2015 and held it in 19 quarters. The position peaked at $191M in Q2 2018. 0 funds tracked by Wall St. Rank hold ONCE as of Q4 2019.

  • JP Morgan Chase reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • JP Morgan Chase sold 499,936 Spark Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $48.5M.
  • JP Morgan Chase first reported a position in Spark Therapeutics, Inc. Common Stock in Q1 2015 and held it in 19 quarters.
  • JP Morgan Chase's Spark Therapeutics, Inc. Common Stock position peaked at $191M in Q2 2018.
  • 0 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q4 2019.

Based on JP Morgan Chase's 13F filing for Q4 2019, filed 11 Feb 2020.